Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CBIO

CBIO - Catalyst Biosciences Inc Stock Price, Fair Value and News

$10.74-0.53 (-4.70%)
Market Closed

24/100

CBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

CBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.24

Target 3M

$11.52

Target 6M

$10.88

CBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CBIO Price Action

Last 7 days

-21.7%

Last 30 days

-11.1%

Last 90 days

-14.1%

Trailing 12 Months

-22.5%

CBIO RSI Chart

CBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CBIO Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

87.55

Price/Sales (Trailing)

9.65

EV/EBITDA

56.62

Price/Free Cashflow

361.63

CBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.24

Target 3M

$11.52

Target 6M

$10.88

CBIO Fundamentals

CBIO Revenue

Revenue (TTM)

107.3M

CBIO Earnings

Earnings (TTM)

11.8M

Earnings Growth (Yr)

107.84%

Earnings Growth (Qtr)

276.65%

CBIO Profitability

EBT Margin

14.24%

Return on Equity

11.59%

Return on Assets

7.41%

Free Cashflow Yield

0.28%

CBIO Investor Care

Dividend Yield

182.79%

Dividend/Share (TTM)

24

Shares Dilution (1Y)

6.13%

Diluted EPS (TTM)

3.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025100.6M102.2M107.3M0
2024115.7M111.6M105.0M105.8M
2023105.1M107.9M110.7M113.5M
202254.8M00102.3M
20216.0M5.5M6.9M7.3M
20209.0M13.0M17.0M20.9M
20185.0M000
2017560.5K562.5K771.5K1.0M
20161.2M436.0K436.0K398.5K
20152.2M2.8M2.3M1.7M
2014845.5K1.2M1.5M1.8M
201338.5M4.9M4.1M523.0K
201281.5M94.4M76.2M57.9M
2011105.2M105.0M102.2M97.6M
2010045.3M65.5M85.7M
200900025.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Catalyst Biosciences Inc

CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcatalystbiosciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Catalyst Biosciences Inc Frequently Asked Questions

CBIO is the stock ticker symbol of Catalyst Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Catalyst Biosciences Inc is 1.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CBIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether CBIO is over valued or under valued. Whether Catalyst Biosciences Inc is cheap or expensive depends on the assumptions which impact Catalyst Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBIO.

As of Wed Jan 28 2026, CBIO's PE ratio (Price to Earnings) is 87.55 and Price to Sales (PS) ratio is 9.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBIO PE ratio will change depending on the future growth rate expectations of investors.